




HEALTHCARE

## **Negotiating the Emerging Biosimilars Landscape**

Key developments in the regulatory environment

Paul Taylor Ph.D. MBA

 [Table of Contents](#)

## **Paul Taylor**

Paul Taylor is an independent market analyst for the medical industry with a BSc and PhD in Biochemistry from the University of Liverpool and an MBA from Oxford Brookes University. Dr Taylor has worked in the medical industry as a senior marketing executive for 20 years creating and implementing strategic business and marketing plans for major multinational medical device companies before establishing himself as an independent research analyst.

For the last ten years Dr Taylor has focused on the structure, organization and functioning of the European health care systems with particular focus on reimbursement systems, analyzing specific European product market segments and advising/preparing strategic business and marketing plans for international pharmaceutical, medical devices and healthcare technology companies.

Copyright © 2008 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Negotiating the Emerging Biosimilars Landscape

### **Executive Summary 10**

<b>Chapter 1: Biosimilars and the biosimilars industry</b>	<b>10</b>
<b>Chapter 2: Factors affecting market access for biosimilars</b>	<b>11</b>
<b>Chapter 3: The European position on biosimilars</b>	<b>12</b>
<b>Chapter 4: The United States' position on biosimilars</b>	<b>13</b>
<b>Chapter 5: Position on biosimilars: China and India</b>	<b>13</b>
<b>Chapter 5: Position on biosimilars: other geographic regions</b>	<b>15</b>

### **Chapter 1 Biosimilars and the biosimilars industry 18**

<b>Summary</b>	<b>18</b>
<b>Introduction and Overview</b>	<b>19</b>
Biotechnology in Healthcare and the Biotechnology Industry	19
Biosimilars: terminology, definitions and nomenclature	20
Biosimilars definitions and terminology	22
Structure of the healthcare based Biotechnology Industry	25
The pharmaceutical-biopharmaceutical relationship	25
Emergence of the biopharmaceutical sector	27
Biopharmaceutical sales by therapeutic area and leading companies	32
Biopharmaceutical sales by therapeutic area	32
Leading biopharmaceutical companies	33
<b>Characteristics and strategy of the biopharmaceutical industry</b>	<b>36</b>
Strategic alliances, joint ventures and mergers	36
High technology and intellectual property issues	37
High venture capital investment	38
High risk and costs associated with drug development	38
<b>Challenges and major Issues</b>	<b>40</b>
The threat from biosimilars	40
Erythropoietins (EPOs).	41
Interferons	44
Human Insulin and Insulins Analogues	49
Monoclonal antibodies (MAb)	51

Lack of regulatory guidelines and legislation controlling biosimilars	53
Product complexity of biopharmaceuticals	53
Differences in immunogenicity	55
Differences in processing and manufacturing	57

## **Chapter 2                      Factors affecting market access for biosimilars                      60**

<b>Summary</b>	<b>60</b>
<b>Introduction</b>	<b>61</b>
<b>Market dynamics</b>	<b>61</b>
Market drivers influencing biosimilars approval, use and uptake	61
Emergence of biosimilars as patents of leading biopharmaceuticals expire	61
Biosimilars predicted to reduce global healthcare costs	62
Advances in manufacturing and proving equivalence provide new impetus to manufacturers	63
Lower priced biosimilars enable greater patient coverage and market penetration	65
EMA legislation relating to biosimilars sets standard for market development of biosimilars in Europe	66
Market restraints influencing biosimilars approval, use and uptake	68
Political lobbying by branded companies	68
Resistance to substitution of products from pharmacists, physicians and patients	68
R&D and commercialization of second generation biopharmaceuticals by innovator companies	69
Manufacturing issues related to bioequivalence and substitutability of branded biopharmaceuticals	70
Biosimilars: The cost and complexity of development	71
Lack of legislation restricts growth of biosimilars in the United States	71
<b>Determining the bioequivalence or essential similarity of biosimilars</b>	<b>73</b>
Proving equivalence of therapeutic proteins	74
Glycosylation	75
Mammalian cell culture processes	76
Glyco-engineered yeast cell lines	77
Proving equivalence of the end product	78
Opinions from originator companies and supporting associations	80
Opinions from generic manufacturers and supporting associations	82
Demonstrating therapeutic equivalence	84
Assays for confirming the presence of antibodies	87
Assays for dissecting the specificity of antibodies	88
Neutralization assays	88

## **Chapter 3                      European position on biosimilars                      92**

<b>Summary</b>	<b>92</b>
<b>European regulation on biosimilars</b>	<b>93</b>
<b>EU legal and regulatory framework for biosimilar products</b>	<b>94</b>
Creation of the European Agency for the Evaluation of Medicinal Products (EMA)	94
Directive 2001/83/EC	97
Directive 2003/63/EC	98
Directive 2004/27/EC	99
Regulatory framework for biosimilars in Europe	101
Principle European guidelines	102
EU specific guidelines on biosimilars (quality & clinical and non clinical issues)	106
EU product specific guidelines on biosimilars	111
<b>Concerns over regulatory, clinical and marketing issues</b>	<b>119</b>
Prohibition of automatic substitution of biosimilars in European countries	119
National interpretations and implementation of the “Bolar Clause”	122
Patient, pharmacist and physician acceptability of biosimilars	124
Reimbursement of biosimilars in Europe	124

## **Chapter 4                      United States position on biosimilars                      129**

<b>Summary</b>	<b>129</b>
<b>Regulation and legislation affecting follow-on biologics in the US</b>	<b>130</b>
Historical background and current legislation in the US	130
Historic legislative developments for biosimilars in the US	133
Recent congressional legislation	141
Access to Life-Saving Medicine Act (H.R. 1038/S.623)	142
Patient Protection and Innovative Biologic Medicines Act (H.R. 1956)	145
S.1695 The Biologics Price Competition and Innovation Act of 2007	147
The Pathways for Biosimilars Act (H.R. 5629)	147
The Federal Trade Commission reviews biosimilars and competition (Notice Billing Code: 6750-01-S)	149
The future outlook for biosimilars in the USA	150

## **Chapter 5                      Position on biosimilars: China and India                      154**

<b>Summary</b>	<b>154</b>
----------------	------------

<b>China</b>	<b>155</b>
Healthcare regulation and legislation in China	155
The Chinese biopharmaceutical and biosimilar industry	157
Regulation and legislation of biologicals in China	166
<b>India</b>	<b>172</b>
Healthcare regulation and legislation in India	172
Establishment of the Central Drug Authority (CDA)	172
Improvements to the administration of biotechnologies in India	173
The biopharmaceutical and biosimilar industry in India	175
Regulation and legislation of biologicals in India	177

## **Chapter 6                      Position on biosimilars: other geographic regions                      182**

<b>Summary</b>	<b>182</b>
<b>Australia</b>	<b>183</b>
Regulation and legislation affecting biopharmaceuticals in Australia	183
Regulatory approval process for medicines in Australia	184
Regulatory approval process for biosimilars in Australia	186
<b>Canada</b>	<b>188</b>
Regulation and legislation affecting biopharmaceuticals in Canada	188
Regulatory approval process for medicines in Canada	188
Current position on subsequent entry biologics in Canada	189
Interim regulatory status of sebs in Canada	191
<b>Japan</b>	<b>192</b>
Healthcare regulation and legislation in Japan	192
Restructuring of principle regulatory agencies in Japan	192
Major changes to pharmaceutical laws enacted April 2005	194
The biopharmaceutical and biosimilar industry in Japan.	197
Current position on follow-on biologicals (fobs) or biosimilars	198

## **Chapter 7                      Appendix                      199**

<b>Methodology statement</b>	<b>199</b>
Primary Data and Information Gathering	199
Secondary data and information gathering	199
Market share analysis and market forecast predictions	201
Definitions of Product-Life Cycle stages	202
<b>Glossary of abbreviations and acronyms</b>	<b>203</b>
<b>Glossary of Terms</b>	<b>211</b>
<b>Index</b>	<b>223</b>

# List of Figures

Figure 1.1:	Evolution of the biopharmaceutical corporation	28
Figure 1.2:	Comparison of global sales by biopharmaceutical class 2007	34
Figure 1.3:	Challenges and Issues Affecting the Biopharmaceutical Industry	42
Figure 1.4:	Predicted market share of multiple sclerosis drugs (2007-2017)	49
Figure 1.5:	Estimated last patent expiry dates of selected proteins	52
Figure 2.6:	Impact of second generation biopharmaceuticals on erythropoietin market development (2000-2006)	70
Figure 2.7:	The process of determining therapeutic equivalence	85
Figure 2.8:	Analytical techniques used to physicochemically characterize complex glycoproteins	89
Figure 3.9:	Structure of the EMEA	96
Figure 3.10:	Timeline of EU guidelines on biosimilars	104
Figure 4.11:	Timeline of US guidelines on follow-on-biologics	141
Figure 5.12:	Biopharmaceutical and pharmaceutical sales revenue in China (2005)	168

# List of Tables

Table 1.1:	Terminology used to describe generic biopharmaceuticals	23
Table 1.2:	Top 20 Pharmaceutical companies ranked by revenue (2007)	30
Table 1.3:	Top 10 Biopharmaceutical companies ranked by revenues (2007)	31
Table 1.4:	Biopharmaceutical sales by therapeutic area, 2007	33
Table 1.5:	Top 10 biopharmaceutical companies biopharmaceutical sales \$m (2003-2007) by ATC3, therapeutic products	35
Table 1.6:	Top 10 biopharmaceutical companies sales \$m (2003-2007) by ATC3, therapeutic products	43
Table 1.7:	Interferons on the market and patent expiries	45
Table 1.8:	Multiple sclerosis drugs on the market and patent expiries	47
Table 1.9:	Recombinant insulin products on the market and patent expiries	51
Table 1.10:	Summary of key structural data for selected therapeutic protein products	54
Table 1.11:	Comparison of biopharmaceuticals versus chemical low molecular weight drugs	55
Table 2.12:	Approved biosimilars EMEA and recommended authorizations	67
Table 2.13:	Productivity increases over the last 20 years in mammalian cell culture	78
Table 2.14:	Physicochemical characterization methodology of non-glycosylated proteins	86
Table 3.15:	Summary of biosimilar overarching guideline (EMEA/CHMP/437/04)	103
Table 3.16:	General EU guidelines on biosimilars	104
Table 3.17:	Summary of Biosimilar Quality Guideline (EMEA/CHMP/49348/05)	108
Table 3.18:	Summary of Biosimilar Non Clinical Guideline (EMEA/CHMP/42832/05)	109
Table 3.19:	Summary of Biosimilars (non) Clinical Guideline Principles for EMEA/CHMP/42832/05	110
Table 3.20:	EU product specific guidelines on biosimilars	115
Table 3.21:	EU revisions to product specific guidelines on biosimilars	115
Table 5.22:	Major biosimilars in China	160
Table 5.23:	Major biosimilar manufacturers in China	161
Table 5.24:	Top 60 Chinese-Owned Biopharmaceutical Companies (Part 1)	164
Table 5.25:	Top 60 Chinese-Owned Biopharmaceutical Companies (Part 2)	164

Table 5.26:	Top 60 Chinese-Owned Biopharmaceutical Companies (Part 3)	165
Table 5.27:	Major biosimilar manufactures based in India	176
Table 5.28:	Major Biosimilars and Manufacturers in India	177